Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Among authors: moots rj. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial.
Bihlet AR, Byrjalsen I, Andersen JR, Reynolds A, Larkins N, Alexandersen P, Rovsing H, Moots R, Conaghan PG. Bihlet AR, et al. Osteoarthritis Cartilage. 2024 Jul;32(7):952-962. doi: 10.1016/j.joca.2024.02.948. Epub 2024 Apr 30. Osteoarthritis Cartilage. 2024. PMID: 38697511 Clinical Trial.
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study.
Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki J, Sopala M, Avrameas A, Luo WL, Hueber W. Dörner T, et al. Among authors: moots rj. Arthritis Rheumatol. 2024 Nov 18. doi: 10.1002/art.43059. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 39557617
British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024.
Murphy R, Moots RJ, Brogan P, Çelik AF, Clement-Jones M, Coulson I, Croft AP, Crozier S, Forrest L, Harrold J, Higgins S, Jawad ASM, Kalra S, Khan SS, McKee H, Pain CE, Petrushkin H, Poveda-Gallego A, Setterfield J, Sharma P, West R, Wlodek C, Hashme M, Manounah L, Mohd Mustapa MF, Constantin AM. Murphy R, et al. Among authors: moots rj. Br J Dermatol. 2024 Oct 17;191(5):e8-e25. doi: 10.1093/bjd/ljae263. Br J Dermatol. 2024. PMID: 39253835 No abstract available.
British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024.
Murphy R, Moots RJ, Brogan P, Çelik AF, Clement-Jones M, Coulson I, Croft AP, Crozier S, Forrest L, Harrold J, Higgins S, Jawad ASM, Kalra S, Khan SS, McKee H, Pain CE, Petrushkin H, Poveda-Gallego A, Setterfield J, Sharma P, West R, Wlodek C, Hashme M, Manounah L, Mohd Mustapa MF, Constantin AM. Murphy R, et al. Among authors: moots rj. Rheumatology (Oxford). 2025 Jan 1;64(1):74-90. doi: 10.1093/rheumatology/keae438. Rheumatology (Oxford). 2025. PMID: 39253811 No abstract available.
192 results